For the first time as a public company, Alnylam Pharmaceuticals announced its quarterly financial results. The company also provided the investment community with an overview of its expectations for upcoming quarters, including the formation of a strategic partnership and the naming of a second therapeutic program.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.